Arca
Skip to content
Tools
Tools

Aplastic anemia

Drug research and approvals for aplastic anemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 69 studies of aplastic anemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 3 approved and 7 open orphan designations naming it.

  • Recruiting worldwide: 69
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 3
  • EU medicines: 0

Recruiting now

Newest posted first, of 69 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 4

Phase 3 7

Phase 2 12 of 16

Phase 1 or earlier 5

How its trials ended

302 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 58 whose ending is known, 38% met their primary endpoint, 9% missed it and 53% stopped early.

  • Completed, result not reported10133%
  • Ongoing9030%
  • Status unknown5318%
  • Met its primary endpoint227%
  • Stopped: enrollment or feasibility134%
  • Stopped: other or unclear124%
  • Missed its primary endpoint52%
  • Stopped: sponsor or business decision31%
  • Stopped: lack of efficacy21%
  • Stopped: safety1<1%

FDA orphan designations

Approved first, then open designations, newest first
Dec 5, 2025OmisirgeTreatment of adults and pediatric patients 6 years of age and older with severe aplastic anemia (SAA) following reduced intensity…Gamida Cell Ltd.Approved
Nov 16, 2018PromactaPROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2…Novartis Pharmaceuticals Corp.Approved
Aug 26, 2014PromactaTreatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.Novartis Pharmaceuticals Corp.Approved
Apr 4, 2025Cord blood derived T regulatory cellsTreatment of aplastic anemiaCellenkos IncDesignated
Nov 27, 2019RomiplostimTreatment of aplastic anemiaAmgen Inc.Designated
May 27, 2015Adult hemogenic endothelial cellsTreatment of aplastic anemiaHemoGenyx LLCDesignated
Feb 18, 2013Allogeneic ex-vivo expanded placental adherent stromal cellsTreatment of Aplastic AnemiaPluri Biotech Ltd.Designated
Nov 3, 1995EtiocholanedioneTreatment of aplastic anemia.SuperGen, Inc.Designated
Jun 17, 1991Interleukin-1 alpha, human recombinantFor hematopoietic potentiation in aplastic anemia.Immunex CorporationDesignated
Sep 25, 1989MolgramostimTreatment of aplastic anemia.Schering CorporationDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.